Stock 6606 NEW HORIZON HEALTH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings New Horizon Health Limited

Equities

6606

KYG6485S1021

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:30 2024-03-27 EDT 		5-day change 1st Jan Change
14.14 HKD -19.75% Intraday chart for New Horizon Health Limited -.--% -38.92%
04-08 New Horizon Health Limited Announces Board Appointments CI
03-28 New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • With an expected P/E ratio at 119.63 and 23.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
NEW HORIZON HEALTH LIMITED Stock New Horizon Health Limited
-38.92% 812M -
BIOMÉRIEUX Stock bioMérieux
-6.61% 11.96B
B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-19.37% 6.6B
B-
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+6.63% 5.75B
B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+27.24% 5.51B
C
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-21.19% 3.48B
C
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.64% 2.51B - -
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+30.09% 2.26B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-66.53% 2.24B
D+
VITROLIFE AB Stock Vitrolife AB
-12.28% 2.19B
B-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 6606 Stock
  4. Ratings New Horizon Health Limited